SetPoint’s neuromodulation implant wins IDE for multiple sclerosis study
SetPoint Medical has been given an investigational device exemption (IDE) from the US Food and Drug Administration (FDA) greenlighting it…
Neurology Devices
-
-
Synchron’s BCI meets primary endpoint in feasibility trial
Synchron has cemented its position as the frontrunner in brain computer interface (BCI) clinical trials, after the company reported positive…
-
Wesper sleep platform reduces nerve stimulation titration time by 45%
New York-based home sleep diagnostics company Wesper has released findings from a case study on hypoglossal nerve stimulation (HGNS) for…
-
Synergia implants first patients with neurostimulator for epilepsy treatment
Synergia Medical has successfully implanted the first two patients in a study evaluating its neurostimulation technology for the treatment of…
-
Onward implants second patient with brain chip in spinal cord injury trial
The implant is part of a feasibility study investigating the ARC-BCI system in spinal cord injury patients who are paralysed…
-
Medtronic teases positive data adaptive deep brain stimulation trial
Medtronic has published preliminary data from a study of its adaptive deep brain stimulation (aDBS) device, Percept PC neurostimulator, in…
-
Onward wins grant from Christopher & Dana Reeve Foundation to advance BCI study
Onward Medical has won a $1.1m grant from the Christopher & Dana Reeve Foundation to support an ongoing study of…
-
Three companies to rival Neuralink in the BCI clinical trial landscape
Neuralink grabbed much of the ‘brain chip’ headlines earlier this month when the company’s founder and owner Elon Musk announced…
-
PhotoPharmics reaches a third of enrolment goal for PD light therapy trial
PhotoPharmics has enrolled the first 100 subjects in its clinical trial investigating a light therapy device designed for the treatment…
-
Magnus Medical tout positive long-term data for neuromodulation system
Magnus Medical has reported positive results from a study investigating the durability of its neuromodulation system’s anti-depressant effect in patients…
